Cero Therapeutics appoints Al Kucharchuk as CFO, Kristen Pierce as CDO

CERo Therapeutics announces key appointments to the Company’s management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named CFO and Kristen Pierce, Ph.D., has been appointed Chief Development Officer. Kucharchuk joins CERo from Nukkelous, Inc. and Chain Bridge I, Inc., both Nasdaq-traded companies where he served as CFO. Prior to joining CERo, Kristen was Vice President, Translational Medicine at Pionyr Therapeutics.